Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-human Study of MORF-440 in Healthy Participants, Including Single and Multiple Ascending Dose Cohorts

NCT06977880 is registered in ClinicalTrials.gov with Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) as lead sponsor.

NCT NCT06977880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06977880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-human Study of MORF-440 in Healthy Participants, Including Single and Multiple Ascending Dose Cohorts
Lead sponsor
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Phase
Phase 1
Overall status
Completed
Start date
February 19, 2025
Completion date
March 20, 2026
Enrollment
80 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy